Clinical Trial Update: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing high-dose recombinant interferon alfa-2B or ipilimumab to pembrolizumab in patients with surgically removed stage III/IV melanoma; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma
• Mucosal Melanoma
• Non-cutaneous Melanoma

Drugs mentioned

• Intron A (interferon alfa-2b)
• KEYTRUDA (PEMBROLIZUMAB)
• Yervoy (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-08-27